ArticlePloS one2025
Systematic analysis of non-melanoma skin cancer burden: A comparative study between China and the world from 1990 to 2021 and prediction to 2036.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the characteristics and trends of the non-melanoma skin cancer (NMSC) burden in China and globally, and to provide a basis for the development of effective prevention and control measures in China.
methodsData related to the incidence, death, and disability-adjusted life years (DALYs) of NMSC in China and the world were obtained from the Global Burden of Disease (GBD) 2021 database. The population included in this sutdy were adults aged 20 and above. The Joinpoint regression model was used to estimate the average annual percentage of change (AAPC) to reflect the time trend. Bayesian age-period-cohort model was constructed for prediction, and the coefficient of determination R² was used to reflect the fitting degree of the model.
resultsFrom 1990 to 2021, the age-standardized incidence rate, mortality rate and DALYs rate of NMSC in China increased by 707.31%, 16.00% and 10.04%, respectively, all higher than the global level. And the corresponding upward trends were also more obvious, with AAPC of 6.71% (95%: 6.01% - 7.18%), 0.46% (95%: 0.40% - 0.52%) and 0.28% (95%: 0.22% - 0.34%), respectively. The incidence rate and its AAPC of NMSC were higher in men than in women. Moreover, the mortality rate and DALYs rate were also higher in men, but the growth rate was faster in women. The high incidence rate, mortality rate, and DALYs rate of NMSC all occurred in the higher age groups. The age-standardized incidence rates of NMSC in China and globally were predicted to continue to rise over the next 15 years, while the age-standardized mortality rates will decline.
conclusionThe burden of NMSC in China remained serious, especially in the context of an increasingly aging population. Relevant authorities should continue to develop and optimize preventive and control measures, especially for men, and adopt targeted measures to reduce the burden of NMSC significantly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.